Association of the 6q23 region with the rate of joint destruction in rheumatoid arthritis

Hans Ulrich Scherer,1,2 Michael P M van der Linden,1 Fina A S Kurreeman,1 Gerrie Stoeken-Rijsbergen,1 Saskia le Cessie,3 Tom W J Huizinga,1 Annette H van der Helm-van Mil,1 René E M Toes1

INTRODUCTION
Recent whole-genome association scans have disclosed novel genetic polymorphisms associated with susceptibility to anti-citrullinated protein/peptide antibody-positive (ACPA+) rheumatoid arthritis (RA).1,2 Among those, two single nucleotide polymorphisms (SNPs), rs675520 and rs9376293, were associated with severity of radiographic joint damage in patients positive for anti-citrullinated protein/peptide antibodies (ACPA). Importantly, the effects were present after correction for confounding factors such as secular trends in treatment.

ABSTRACT
Background Two novel genetic polymorphisms on chromosome 6q23 are associated with susceptibility to rheumatoid arthritis (RA). Both polymorphisms (rs6920220 and rs10499194) reside in a region close to the gene encoding tumour necrosis factor α-induced protein 3 (TNFAIP3). TNFAIP3 is a negative regulator of NF-κB and is involved in inhibiting TNF-receptor-mediated signalling effects. Interestingly, the initial associations were detected in patients with longstanding RA. However, no association was found for rs10499194 in a Swedish cohort with early arthritis. This might be caused by over-representation of patients with severe disease in cohorts with longstanding RA.

Objective To analyse the effect of the 6q23 region on the rate of joint destruction.

Methods Five single nucleotide polymorphisms in 6q23 were genotyped in 324 Dutch patients with early RA. Genotypes were correlated with progression of radiographic joint damage for a follow-up time of 5 years.

Results Two polymorphisms (rs675520 and rs9376293) were associated with severity of radiographic joint damage in patients positive for anti-citrullinated protein/peptide antibodies (ACPA). Importantly, the effects were present after correction for confounding factors such as secular trends in treatment.

Conclusions These data associate the 6q23 region with the rate of joint destruction in ACPA+ RA.

PATIENTS AND METHODS
Patients The Leiden EAC is a population-based inception cohort that includes patients with self-reported symptom duration of ≤2 years. DNA samples of 324 patients consecutively included between 1993 and 2003 were used for analysis. For further details see online supplementary file 1.

SNP selection and genotyping
Five SNPs (rs1878658, rs675520, rs9376293, rs10499194 and rs6920220) were selected based on a haplotype analysis across the 6q23 locus published previously.2 All SNPs are in imperfect linkage disequilibrium with one another (supplementary table 1). Genotyping was performed using presdesigned TaqMan allelic discrimination probes (Applied Biosystems, Foster City, California, USA). Each 96-well plate contained 10 ng sample DNA per well and at least eight negative and six positive controls. Genotype calls and clusters were further replicated in an extended UK-based case-control study.4 rs10499194 was initially identified in North American ACPA+ patients (the Brigham Rheumatoid Arthritis Sequential Study, BRASS; minor allele OR=0.67).2 Replication was successful in two additional US cohorts selected from the North American Rheumatoid Arthritis Consortium (NARAC). Replication failed, however, in ACPA+ patients of a Swedish population-based inception cohort (the Epidemiological Investigation of Rheumatoid Arthritis cohort, EIRA).3 This last finding is of interest, as BRASS and NARAC are cohorts of patients with longstanding RA (mean disease duration BRASS: 15.4±12.8 years; NARAC: 14.3±11.1 years).5 The EIRA study, however, was designed to identify incident cases of RA as soon as possible after disease onset, resulting in an estimated mean disease duration at inclusion of only 10 months.7

Association of a genetic polymorphism in cohorts of patients with longstanding disease but absence of this association in an early arthritis cohort led us to hypothesise that the 6q23 region would be associated with disease severity in ACPA+ patients. Very little information is currently available on the effects of genetic variation on outcome measures in RA.8 Therefore, we genotyped five SNPs in a Dutch early arthritis cohort (the Leiden Early Arthritis Clinic, EAC) and correlated genotyping data to progression of radiographic joint damage for a maximum follow-up of 5 years.
RESULTS

Radiographic scores of 324 Dutch patients with RA (181 ACPA+, 143 ACPA−) were available for analysis. At least five radiographic follow-up observations were available in 57% of patients. A dominant model was chosen for analysis, as the frequency of patients homozygous for the minor allele of rs1878658 (G), rs10499194 (T) and rs6920220 (A) was ≤5%. Figure 1 depicts the influence of genotypes on radiographic joint damage. ACPA+ and ACPA− subgroups were analysed separately. Median scores and interquartile ranges (IQR) are provided for ACPA+ patients in table 1 (for ACPA− patients, see supplementary table 2).

No influence of genotypes on radiographic joint damage was seen in ACPA− patients (fig 1). In ACPA+ patients, however, two polymorphisms showed reproducible association with disease progression over time. Presence of the G allele of rs675520 was found to be associated with increased Sharp van der Heijde scores, as a significant difference was observed when the average increase (slope) in radiographic scores over time was compared with G as the dominant allele (median slope AG/GG=4.6, AA=2.3; Mann–Whitney p=0.007). In order to account for an effect of improving treatment strategies on radiographic progression during the 10-year period in which patients were included in the study, we next performed a mixed-model analysis. This analysis identified the year of inclusion as a significant variable influencing the extent of radiographic joint damage (p=0.005). After correcting for the year of inclusion, however, we still observed a significant influence of the G allele of rs675520 (AG/GG vs AA, p=0.026).

Similar to the G allele of rs675520, we noted an influence of the C allele of rs9376293 on progression of radiographic joint damage (fig 1). The average increase (slope) in Sharp van der Heijde scores over time was significantly higher for C allele carriers than for T homozygotes (median slope CC/CT=4.6, median slope TT=3.0, Mann–Whitney p=0.021). After correcting for the year of inclusion as described above a trend effect of the C allele remained (p=0.097).

For rs1878658, rs10499194 and rs6920220, no significant influence of individual genotypes on radiographic joint damage was noted.
but not in an early arthritis cohort. This indicated a potential candidates which may modulate inflammation also in RA. The 6q23 region has recently been associated with disease susceptibility in ACPA+ patients with RA in three cohorts with longstanding disease, in cohorts with differing disease duration. The major allele (C) was shown to identify common haplotypes in 6q23. We identified two SNPs for which the presence of alleles was associated with increased joint destruction in ACPA+ patients. Carriers of the G allele of rs675520 developed increased Sharp van der Heijde scores over time. A similar effect, although weaker, was found for the C allele of rs9376293. Interestingly, no association was found for any of the SNPs in ACPA− subjects. Although this does not exclude the possibility of a contribution of the 6q23 region to disease severity in ACPA− disease, the latter observation is in line with recent reports detecting an association of the 6q23 region with disease susceptibility in ACPA+ patients only.

No effect on disease severity was observed for rs10499194 and rs6920220. Based on our data we cannot rule out the possibility that either SNP exerts a weak effect that requires larger sample numbers for detection or that cannot be observed during the first years of disease. Interestingly, we observed nominally higher scores for the risk-conferring A allele of rs6920220 without reaching statistical significance. The discrepancy between SNPs associating with susceptibility and radiographic progression also indicates that the causal variant at this locus has not yet been identified. Given the large area of linkage disequilibrium surrounding these SNPs, further fine-mapping and functional characterisation will have to be performed.

Data linking newly identified genetic polymorphisms to disease outcome in RA are only beginning to emerge. Our data are unique, as they cover a long period of radiographic follow-up and have been scrutinised for artefacts such as secular trends in treatment intensity. Albeit based on relatively small patient numbers, our data indicate a contribution of the 6q23 region to the rate of joint destruction in ACPA+ RA, thereby further refining our understanding of the effects exerted by this locus. Replication of our findings in other cohorts is needed. Nonetheless, this is the first study demonstrating such an effect for genetic polymorphisms located outside the HLA-region in ACPA+ patients with RA.

**DISCUSSION**

The 6q23 region has recently been associated with disease susceptibility in RA. This region contains no known transcripts. The closest genes with known function are OLIG3 and TNFAIP3. TNFAIP3 encodes protein A20, a TNFα-induced negative regulator of NF-κB. Decreased levels of A20 lead to uncontrolled NF-κB activity, resulting in increased inflammation. This observation makes TNFAIP3/A20 and the 6q23 region interesting candidates which may modulate inflammation also in RA.

We were intrigued by recent differential findings for rs10499194, a SNP on chromosome 6q23 close to TNFAIP3, in cohorts with differing disease duration. The major allele (C) was found to be associated with disease susceptibility in ACPA+ patients with RA in three cohorts with longstanding disease, but not in an early arthritis cohort. This indicated a potential impact of the 6q23 region on disease severity. In order to test for such an impact, five SNPs were genotyped in a cohort of Dutch patients with early RA. These SNPs had previously been shown to identify common haplotypes in 6q23. We identified two SNPs for which the presence of alleles was associated with increased joint destruction in ACPA+ patients. Carriers of the G allele of rs675520 developed increased Sharp van der Heijde scores over time. A similar effect, although weaker, was found for the C allele of rs9376293. Interestingly, no association was found for any of the SNPs in ACPA− subjects. Although this does not exclude the possibility of a contribution of the 6q23 region to disease severity in ACPA− disease, the latter observation is in line with recent reports detecting an association of the 6q23 region with disease susceptibility in ACPA+ patients only.

No effect on disease severity was observed for rs10499194 and rs6920220. Based on our data we cannot rule out the possibility that either SNP exerts a weak effect that requires larger sample numbers for detection or that cannot be observed during the first years of disease. Interestingly, we observed nominally higher scores for the risk-conferring A allele of rs6920220 without reaching statistical significance. The discrepancy between SNPs associating with susceptibility and radiographic progression also indicates that the causal variant at this locus has not yet been identified. Given the large area of linkage disequilibrium surrounding these SNPs, further fine-mapping and functional characterisation will have to be performed.

Data linking newly identified genetic polymorphisms to disease outcome in RA are only beginning to emerge. Our data are unique, as they cover a long period of radiographic follow-up and have been scrutinised for artefacts such as secular trends in treatment intensity. Albeit based on relatively small patient numbers, our data indicate a contribution of the 6q23 region to the rate of joint destruction in ACPA+ RA, thereby further refining our understanding of the effects exerted by this locus. Replication of our findings in other cohorts is needed. Nonetheless, this is the first study demonstrating such an effect for genetic polymorphisms located outside the HLA-region in ACPA+ patients with RA.

**ACKNOWLEDGEMENTS**

We are grateful to Robert M. Plenge for sharing genotyping data on polymorphisms in 6q23.

**FUNDING**

Dutch Arthritis Foundation; European Community FP6 funding project 018661 Autocore and FP7 funding project Masterswitch; Pfizer Articulum Fellowship; Centre for Medical Systems Biology (CMiSB) within the framework of the Netherlands Genomics Initiative (NGI); The Netherlands Organization for Health Research and Development.

**COMPETING INTERESTS**

None.

**ETHICS APPROVAL**

This study was conducted with the approval of the Institutional Review Board of Leiden University Medical Centre, Leiden, The Netherlands.

**CONTRIBUTORS**

HUS designed the study, performed genotyping, analysed and interpreted data and wrote the manuscript; MPMvdL performed x-ray scoring; GSR interpreted data and wrote the manuscript; REMT designed the study, interpreted data and critically drafted and revised the manuscript. All authors approved the submitted version.

**ACKNOWLEDGEMENTS**

We are grateful to Robert M. Plenge for sharing genotyping data on polymorphisms in 6q23.

**FUNDING**

Dutch Arthritis Foundation; European Community FP6 funding project 018661 Autocore and FP7 funding project Masterswitch; Pfizer Articulum Fellowship; Centre for Medical Systems Biology (CMiSB) within the framework of the Netherlands Genomics Initiative (NGI); The Netherlands Organization for Health Research and Development.

**COMPETING INTERESTS**

None.

**ETHICS APPROVAL**

This study was conducted with the approval of the Institutional Review Board of Leiden University Medical Centre, Leiden, The Netherlands.

**CONTRIBUTORS**

HUS designed the study, performed genotyping, analysed and interpreted data and wrote the manuscript; MPMvdL performed x-ray scoring; GSR interpreted data and wrote the manuscript; REMT designed the study, interpreted data and critically drafted and revised the manuscript. All authors approved the submitted version.

**PROVENANCE AND PEER REVIEW**

Not commissioned; externally peer reviewed.

**REFERENCES**

Association of the 6q23 region with the rate of joint destruction in rheumatoid arthritis

Hans Ulrich Scherer, Michael P M van der Linden, Fina A S Kurreeman, Gerrie Stoeken-Rijsbergen, Saskia le Cessie, Tom W J Huizinga, Annette H van der Helm-van Mil and René E M Toes

Ann Rheum Dis 2010 69: 567-570 originally published online April 14, 2009
doi: 10.1136/ard.2008.106161

Updated information and services can be found at:
http://ard.bmj.com/content/69/3/567

These include:

Supplementary Material
Supplementary material can be found at:
http://ard.bmj.com/content/suppl/2010/04/16/ard.2008.106161.DC1

References
This article cites 11 articles, 3 of which you can access for free at:
http://ard.bmj.com/content/69/3/567#BIBL

Open Access
This paper is freely available online under the BMJ Journals unlocked scheme, see http://ard.bmj.com/info/unlocked.dtl

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Open access (595)
Connective tissue disease (4253)
Degenerative joint disease (4641)
Immunology (including allergy) (5144)
Musculoskeletal syndromes (4951)
Rheumatoid arthritis (3258)
Genetics (968)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/